Revenio: Not a one-trick pony
Revenio is known as the global beacon of tonometers but these days the company is a noteworthy challenger in more extensive ophthalmic health technology. Imaging tools (previous CenterVue) play an increasing role in future growth and HOME products, as well as software business offer longer term growth promises. Business is growing very profitably, the market has sound growth drivers, and the products have strong competitive advantages. In addition, the company has an excellent track record of its ability to create value with investments in product development, structural reorganization, and new long-term growth templates
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Read more on company pageKey Estimate Figures2021-06-08
| 2020 | 21e | 22e | |
|---|---|---|---|
| Revenue | 61.1 | 79.3 | 102.5 |
| growth-% | 23.4 % | 29.9 % | 29.2 % |
| EBIT (adj.) | 19.2 | 27.2 | 37.1 |
| EBIT-% (adj.) | 31.4 % | 34.3 % | 36.2 % |
| EPS (adj.) | 0.58 | 0.82 | 1.10 |
| Dividend | 0.32 | 0.40 | 0.55 |
| Dividend % | 0.6 % | 3.3 % | 4.5 % |
| P/E (adj.) | 86.6 | 15.0 | 11.2 |
| EV/EBITDA | 61.5 | 11.5 | 7.9 |
Forum discussions
